BACKGROUND AND PURPOSE: Proton MR spectroscopy ((1)H-MR spectroscopy) is a well-established method for the in vivo investigation of the normal-appearing white matter (NAWM) in patients with multiple sclerosis (MS). Metabolic changes in NAWM are of special interest in patients with clinically isolated syndromes (CIS) suggestive of MS regarding further prognostic classifications. The purpose of this study was to investigate metabolic alterations in NAWM in patients with CIS with use of high-field (1)H-MR spectroscopy and to compare the results to those in patients with an early course of MS. MATERIALS AND METHODS: With use of a 3T whole-body MR imaging system, single-voxel (1)H-MR spectroscopy (PRESS; TR: 2000 ms; TE: 38 ms and 140 ms) of the parietal NAWM was performed in 20 control subjects, 36 patients with CIS, and 12 patients with MS. Metabolite ratios and concentrations of N-acetylaspartate (tNAA), myo-inositol (mIns), choline, and total creatine (tCr) were determined. RESULTS: Compared with the control group, mean NAWM mIns concentrations were significantly elevated in the MS group (4.56 mmol/L versus 3.75 mmol/L, P = .02) but not in the CIS group (4.04 mmol/L, P = .44). The higher concentration of mIns in the MS group was also reflected in the increased Ins/tCr ratio (P = .02). The mean NAWM tNAA was significantly decreased in both patient groups compared with the control group (CIS, 13.42 mmol/L, P = .02; MS, 12.77 mmol/L versus 14.51 mmol/L, P = .008). CONCLUSIONS: A significant increase of the activity of the glial cells can only be observed in patients with an established diagnosis of MS but not in patients with CIS. Axonal damage occurs already during the first demyelinating episode in patients with CIS as well as in patients with definite MS.
BACKGROUND AND PURPOSE: Proton MR spectroscopy ((1)H-MR spectroscopy) is a well-established method for the in vivo investigation of the normal-appearing white matter (NAWM) in patients with multiple sclerosis (MS). Metabolic changes in NAWM are of special interest in patients with clinically isolated syndromes (CIS) suggestive of MS regarding further prognostic classifications. The purpose of this study was to investigate metabolic alterations in NAWM in patients with CIS with use of high-field (1)H-MR spectroscopy and to compare the results to those in patients with an early course of MS. MATERIALS AND METHODS: With use of a 3T whole-body MR imaging system, single-voxel (1)H-MR spectroscopy (PRESS; TR: 2000 ms; TE: 38 ms and 140 ms) of the parietal NAWM was performed in 20 control subjects, 36 patients with CIS, and 12 patients with MS. Metabolite ratios and concentrations of N-acetylaspartate (tNAA), myo-inositol (mIns), choline, and total creatine (tCr) were determined. RESULTS: Compared with the control group, mean NAWM mIns concentrations were significantly elevated in the MS group (4.56 mmol/L versus 3.75 mmol/L, P = .02) but not in the CIS group (4.04 mmol/L, P = .44). The higher concentration of mIns in the MS group was also reflected in the increased Ins/tCr ratio (P = .02). The mean NAWM tNAA was significantly decreased in both patient groups compared with the control group (CIS, 13.42 mmol/L, P = .02; MS, 12.77 mmol/L versus 14.51 mmol/L, P = .008). CONCLUSIONS: A significant increase of the activity of the glial cells can only be observed in patients with an established diagnosis of MS but not in patients with CIS. Axonal damage occurs already during the first demyelinating episode in patients with CIS as well as in patients with definite MS.
Authors: M P Wattjes; M Harzheim; C K Kuhl; J Gieseke; S Schmidt; L Klotz; T Klockgether; H H Schild; G G Lutterbey Journal: AJNR Am J Neuroradiol Date: 2006-09 Impact factor: 3.825
Authors: J H Simon; D Li; A Traboulsee; P K Coyle; D L Arnold; F Barkhof; J A Frank; R Grossman; D W Paty; E W Radue; J S Wolinsky Journal: AJNR Am J Neuroradiol Date: 2006-02 Impact factor: 3.825
Authors: D Wiedermann; N Schuff; G B Matson; B J Soher; A T Du; A A Maudsley; M W Weiner Journal: Magn Reson Imaging Date: 2001-10 Impact factor: 2.546
Authors: M D Keiper; R I Grossman; J A Hirsch; L Bolinger; I L Ott; L J Mannon; C P Langlotz; D L Kolson Journal: AJNR Am J Neuroradiol Date: 1998-09 Impact factor: 3.825
Authors: Mike P Wattjes; Götz G Lutterbey; Michael Harzheim; Jürgen Gieseke; Frank Träber; Luisa Klotz; Thomas Klockgether; Hans H Schild Journal: Eur Radiol Date: 2006-04-04 Impact factor: 5.315
Authors: S M Leary; C A Davie; G J Parker; V L Stevenson; L Wang; G J Barker; D H Miller; A J Thompson Journal: J Neurol Date: 1999-11 Impact factor: 4.849
Authors: P A Brex; B Gomez-Anson; G J Parker; P D Molyneux; K A Miszkiel; G J Barker; D G MacManus; C A Davie; G T Plant; D H Miller Journal: J Neurol Sci Date: 1999-06-15 Impact factor: 3.181
Authors: Barbara Maria Krauspe; Wolfgang Dreher; Cordian Beyer; Werner Baumgartner; Bernd Denecke; Katharina Janssen; Claus-Dieter Langhans; Tim Clarner; Markus Kipp Journal: J Mol Neurosci Date: 2014-09-05 Impact factor: 3.444
Authors: Mike P Wattjes; Michael Harzheim; Götz G Lutterbey; Manuela Bogdanow; Stephan Schmidt; Hans H Schild; Frank Träber Journal: Neuroradiology Date: 2007-11-03 Impact factor: 2.804
Authors: Fahmy Aboul-Enein; Martin Krssák; Romana Höftberger; Daniela Prayer; Wolfgang Kristoferitsch Journal: PLoS One Date: 2010-07-20 Impact factor: 3.240
Authors: Mike P Wattjes; Michael Harzheim; Götz G Lutterbey; Manuela Bogdanow; Hans H Schild; Frank Träber Journal: J Neurol Date: 2007-12-20 Impact factor: 4.849
Authors: Emily T Wood; Itamar Ronen; Aranee Techawiboonwong; Craig K Jones; Peter B Barker; Peter Calabresi; Daniel Harrison; Daniel S Reich Journal: J Neurosci Date: 2012-05-09 Impact factor: 6.167